

3. Results

3.1. Establishment of initiation assay

Preliminary examination with MNNG and MCA in the Bhas promotion assay revealed little response in the formation of transformed foci. Then, an experimental

procedure was designed in which Bhas 42 cells were seeded at one-tenth lower cell density (2×10^3 cells/mL) than in the promotion assay (2×10^4 cells/mL), a procedure that will permit cells to divide several times after the treatment with test chemicals. With the protocol described in Section 2.4, MNNG and MCA induced a significant number of foci (Fig. 1A and C).




Fig. 1. Results of transformation assays of initiators. A, C and E show results of initiation assay and B, D and F show results of promotion assay. G shows result of metabolic activation in AFB₁ initiation assay. * $p < 0.05$, compared with solvent control. ** $p < 0.01$, compared with solvent control.




Fig. 2. Results of transformation assays of promoters. A, C and E show results of initiation assay and B, D and F show results of promotion assay. * $p < 0.05$, compared with solvent control. ** $p < 0.01$, compared with solvent control.




Fig. 3. Result of transformation assay under various time schedules. In treatment schedule, solid blocks represent treatment with 100 ng/mL MCA and diagonal blocks represent treatment with 50 ng/mL TPA.

3.2. Transformation assays of initiators

The results are summarized in Table 1. Fig. 1A and B shows the results of Bhas initiation and promotion assays of MNNG, respectively. Significant increase of focus formation was observed in the initiation assay at the concentrations of 0.5 $\mu\text{g/mL}$ and above. As mentioned above, MNNG did not induce transformed foci in the promotion assay up to 0.1 $\mu\text{g/mL}$. With concentrations over 0.2 $\mu\text{g/mL}$ in the promotion assay, cell flattening with enlarged cell size and without increased cell number was observed after triple dosing with concentrations over 0.2 $\mu\text{g/mL}$ in the promotion assay.

Results of the initiation and promotion assays for MCA are shown in Fig. 1C and D. MCA showed a response similar to that with MNNG. MCA induced transformed foci in the initiation assay at concentrations of 0.5 $\mu\text{g/mL}$ and higher. In the case of the promotion assay, no focus formation was observed at concentrations up to 0.1 $\mu\text{g/mL}$ and severe cytotoxicity was observed at concentrations over 0.2 $\mu\text{g/mL}$.

AFB₁ showed negative results in both initiation and promotion assays (Fig. 1E and F). In the case of promotion assay, 1 $\mu\text{g/mL}$ of AFB₁ was the maximum concentration tested because of its cytotoxicity. Metabolic activation of AFB₁ by cytochrome P450 (CYP) 2A6, 3A4 and 1A2 is necessary to exert mutagenic and carcinogenic activities [24,25]. Fig. 1G shows results of the initiation assay of AFB₁ metabolically activated by S9

mix, and there was significant foci induction at 1 and 2 $\mu\text{g/mL}$.

3.3. Transformation assays of tumor promoters

Initiation and promotion activities of three tumor promoters were also examined and the results are summarized in Table 1. Fig. 2A and B shows results on TPA. No increase of focus number was observed in the initiation assay up to 100 ng/mL (Fig. 2A). In contrast, significant increase of focus formation was observed in the promotion assay at all concentrations tested up to 100 ng/mL (Fig. 2B).

Fig. 2C and D shows results on LCA. As in the case of TPA, transformed foci were not induced in the initiation assay at all concentrations tested (Fig. 2C), whereas transformed foci were observed in the promotion assay at all concentrations tested (Fig. 2D).

Okadaic acid, up to 10 ng/mL, did not induce transformed foci (Fig. 2E) in the initiation assay. A significant increase of focus formation was observed in the promotion assay at 8 and 10 ng/mL at which high cytotoxicity was shown (Fig. 2F).

3.4. Transformation assays with various schedules of treatment

Fig. 3 shows results of treatment with MCA (100 ng/mL) and/or TPA (50 ng/mL) under various treat-




Fig. 4. Results of initiation and promotion assays of B[a]P and DMBA (Group I). A and C show results of initiation assay and B and D show results of promotion assay. * $p < 0.05$, compared with solvent control. ** $p < 0.01$, compared with solvent control.

ment schedules. When Bhas 42 cells were seeded at 2×10^3 cells/mL, cells were in growth phase almost until Day 7. In order to treat cells repeatedly during the period of growth phase, change of medium containing MCA or TPA was performed every 2 days (periods 1–3 in Fig. 3). After Day 7, when cells became confluent, the change of MCA- or TPA-containing medium was carried out twice a week during the subsequent period (periods 4–6 in Fig. 3).

Schedules B–E were performed as confirmation test of initiation and promotion assays for MCA and TPA. The number of transformed foci in Schedule F did not increase from that in Schedule B, indicating that the additional treatment with MCA during stationary phase had little effect. In contrast, MCA-treatment during cell-growth phase followed by TPA-treatment during stationary phase clearly enhanced the formation of transformed foci (Schedule G). Repeated treatment with MCA during




Fig. 5. Results of initiation and promotion assays of B[e]P, B[ghi]P, 1-NP and pyrene (Group II). A, C, E and G show results of initiation assay and B, D, F and H show results of promotion assay. * $p < 0.05$, compared with solvent control. ** $p < 0.01$, compared with solvent control.

the cell-growth phase (Schedule H) and the whole period (Schedule J) increased the number of transformed foci. It is remarkable that cell growth was retarded and cells did not reach subconfluence on Day 7 because of the cytotoxicity of MCA. Repeated TPA treatment during growth phase (Schedule I) was ineffective for inducing transformed foci. The number of transformed foci in Schedule K (TPA treatment during cell-growth phase and stationary phase) did not increase from that in Schedule E.

3.5. Initiation and promotion assays of PAHs

Results described above showed that MCA induced foci in the initiation assay without metabolic activation by S9 mix. This means that Bhas 42 cells have the capacity to metabolize PAHs, like the parental cell line BALB/c 3T3. Sixteen PAHs were evaluated for their initiating and promoting activities using the present methods. Response to PAHs in both methods could be categorized into four groups: showing only initiation




Fig. 6. Results of initiation and promotion assays of B[a]A, B[b]A, chrysene and perylene (Group III). A, C, E and G show results of initiation assay and B, D, F and H show results of promotion assay. * $p < 0.05$, compared with solvent control. ** $p < 0.01$, compared with solvent control.




Fig. 7. Results of initiation and promotion assays of acenaphthylene, coronene and 9,10-DPhA (Group IV). A, C and E show results of initiation assay and B, D and F show results of promotion assay. * $p < 0.05$, compared with solvent control. ** $p < 0.01$, compared with solvent control.

activity (Group I), only promotion activity (Group II), both initiation and promotion activities (Group III), and equivocal or negative response in both methods (Group IV).

Fig. 4 shows results of two chemicals showing positive responses only in the initiation assay (Group I). B[a]P at concentrations of 0.5 and 1 µg/mL (Fig. 4A) and DMBA at concentrations of 10 ng/mL and above (Fig. 4C) induced transformed foci in the initiation assay only. In the case of the promotion assay, no transformed foci were induced at any concentrations tested for B[a]P (Fig. 4B) or DMBA (Fig. 4D).

Chemicals classified in Group II consisted of B[e]P, B[ghi]P, 1-NP, and pyrene, which showed positive responses only in the promotion assay (Fig. 5). No increase of foci was observed in the initiation assay with these chemicals (Fig. 5A, C, E and G). In contrast, they induced significant increase of foci in the promotion assay (Fig. 5B, D, F and H).

Results for Group III are shown in Fig. 6. B[a]A at concentrations of 0.5 µg/mL and above (Fig. 6A), chrysene at concentrations of 0.2 µg/mL and above (Fig. 6E) and perylene at concentrations of 1 µg/mL and above (Fig. 6G) induced foci in the initiation assay. In the initiation assay of B[b]A, the number of foci increased on increasing the dose up to 0.1 µg/mL, but it decreased at concentrations over 0.2 µg/mL (Fig. 6C). In the promotion assay, a marked increase in focus formation was observed with these chemicals at a non-cytotoxic concentration range from 0.1 to 10 µg/mL (Fig. 6B, D, F and H).

Fig. 7 shows results of initiation and promotion assays of acenaphthylene, coronene, and 9,10-DPhA. No increase of foci was observed in the initiation assay at all concentrations tested for acenaphthylene (Fig. 7A), coronene (Fig. 7C) and 9,10-DPhA (Fig. 7E). These chemicals weakly induced foci in the promotion assay at the highest concentration (Fig. 7B, D and F). Results of initiation and promotion assays for anthracene, naph-




Fig. 8. Results of initiation and promotion assays of anthracene, naphthalene and phenanthrene (Group IV). A, C and E show results of initiation assay and B, D and F show results of promotion assay. * $p < 0.05$, compared with solvent control. ** $p < 0.01$, compared with solvent control.

thalene, and phenanthrene are shown in Fig. 8. These chemicals were entirely negative in both initiation and promotion assays at concentrations up to 10 µg/mL.

4. Discussion

In addition to the Bhas promotion assay, we have developed a method for evaluation of initiating activity of chemicals using Bhas 42 cells. In the promotion assay, cells are treated with test chemicals at subconfluent condition, in which further cell division is limited, whereas the initiation assay was designed for cells at a lower cell density to be able to divide several times after treatment with test chemicals. The fact that tumor initiators could transform Bhas 42 cells only under cell proliferating conditions was important in aiding understanding of the two-stage model of chemical carcinogenesis. MNNG and MCA, both tumor initiators, were positive in the initiation assay but negative in the promotion assay. In contrast, TPA, LCA, and okadaic acid, tumor promoters

[26–31], were positive in the promotion assay but were negative in the initiation assay.

Some tumor initiators are considered to have tumor-promoting activity. This recognition came from the experimental observation that repeated application at subtumorigenic doses can induce tumors in mouse skin without any post-treatment with a promoter [1]. In order to probe why repeated treatment with MNNG or MCA could not induce transformed foci in the Bhas promotion assay, an experiment with various schedules of treatment was conducted (Fig. 3). This demonstrated that MCA was effective only when cells were in a dividing phase, consistent to the current notion for the mechanism of initiator action, i.e., the fixation of genetic damage resulting in genetic alteration, namely mutation, after several cell divisions. On the contrary, the promoter, TPA, induced transformed foci when cell division was limited but it was not effective during the cell-dividing phase. It is well known that tumor promoters inhibit the interaction with neighboring cells (metabolic cooperation) [32–35].

Table 2
Summary of Bhas initiation and promotion assays for 22 tested chemicals, and published carcinogenicity and mutagenicity assay summaries

Chemical	CAS no.	IARC	Bhas 42 assay		In vivo carcinogenicity ^a	Ames' test		Missense mutation ^c		E. coli		Metabolic cooperation		MLA		References
			Initiation assay	Promotion assay		Carcinogenicity	Promotion	Frameshift mutation ^b	S9 (-)	S9 (+)	S9 (-)	S9 (+)	S9 (-)	S9 (+)	S9 (-)	
Group I																
MNNG	70-25-7	2A	+	-	+	+	+	+	+	+	+	+	+	+	+	[42,44-46,48,50,55]
MCA	56-49-5		+	-	+	+	+	+	-	-	-	+	+	+	+	[42,44,45,48,55]
B[a]P	50-32-8	2A	+	-	+	+	+	+	+	-	-	-	-	-	+	[38,41,42,55,57,61]
DMBA	57-97-6		+	-	+	+	+	+	+	-	-	+	+	+	+	[41,42,44,48,55,60]
AFB1	1162-65-8	1	+ ^d	-	+ ^e	+	I	+	+	-	-	-	-	-	+	[39,42,55]
Group II																
TPA	16561-29-8		-	+	-	+	-	-	-	-	-	+	+	-	-	[1,42,62]
LCA	434-13-9		-	+	-	+	-	-	-	-	-	+	+	-	-	[41,44,47,60,62]
Okadaic acid	78111-17-8		-	+	-	+	-	-	-	-	-	-	I	-	-	[30,54,56]
B[e]P	192-97-2	3	-	+	-	+	-	-	-	-	-	-	-	-	-	[38,41-44]
B[ghi]P	191-24-2	3	-	+	-	+	-	-	-	-	-	-	-	-	-	[38,41,49,50]
I-NP	5522-43-0	2B	-	+	+	+	I	I	I	-	-	-	-	-	-	[39,49,50,58]
Pyrene	129-00-0	3	-	+	-	+	I	-	-	-	-	-	-	-	-	[38,41,42,44]
Group III																
B[a]A	56-55-3	2A	+	+	+	+	+	+	+	-	-	-	+	-	-	[38,42,53,55]
B[b]A	92-24-0		+	+	+	+	+	+	+	-	-	-	-	-	-	[51]
Chrysene	218-01-9	3	+	+	+	+	+	+	+	-	-	-	-	-	-	[38,41,42,59]
Perylene	198-55-0	3	+	+	-	-	-	-	-	+	+	-	-	+	+	[38,41,50,52,60]
Group IV																
Acenaphthylene	208-96-8		-	±	-	-	-	-	-	-	-	-	-	-	-	[38,41,42,44,60]
Anthracene	120-12-7	3	-	-	-	-	-	-	-	-	-	-	-	-	-	[38,41,43]
Coronene	191-07-1	3	-	±	+	-	-	-	-	-	-	-	-	-	-	[40-42]
9,10-DPhA			-	±	-	-	-	-	-	-	-	-	-	-	-	[38,41,42,44]
Naphthalene	91-20-3	2B	-	-	-	-	-	-	-	-	-	-	-	-	-	
Phenanthrene	85-01-8	3	-	-	-	-	-	-	-	-	-	-	-	-	-	

+, positive result; -, negative result; ±, equivocal result; I, inconclusive result.

^a Carcinogenicity was tested by skin application to mice and promoting activity was assessed by mouse-skin initiation-promotion assay.

^b Frameshift mutation was detected with TA97, TA98, TA1537 and TA1538.

^c Missense mutation was detected with TA100 and TA1535.

^d Initiating activity of AFB1 required metabolic activation with S9.

^e Carcinogenicity of AFB1 was shown in liver.

Tsuchiya and Umeda [36] have demonstrated that a subconfluent phase of MNNG-initiated BALB/c 3T3 cells was the most sensitive stage for the induction of transformed foci by TPA.

Bhas 42 cells were considered as initiated cells by virtue of transfection of the *v-Ha-ras* gene. Here, however, we demonstrated that the additional treatment with initiating chemicals is effective for inducing transformed foci. Carcinogenesis is now considered to be a multi-step phenomenon. Sugimura stated in his review that several mutations could lead to tumor formation [37]. Thus, the results are interpreted as showing that initiator-induced mutations of oncogene(s) other than *ras* oncogene in Bhas 42 cells can result in the induction of cell transformation.

These discussions may pertain to a specific *in vitro* experimental assay, but the phenomena support the hypothetical mechanism for tumor formation in the mouse skin, where repeated treatment with tumor initiator causes genetic damage of several oncogenes in the skin cells. The basement cell layer of mouse skin comprises actively dividing stem cells, wherein genetic damage can be fixed and result in mutations. Therefore, we hypothesize that tumor formation from tumor initiator exposure does not involve promoting activity, such as disturbed interaction between neighboring cells, i.e., loss of metabolic cooperation, but involves fixation and accumulation of genetic damage after cell divisions.

In order to investigate the applicability of Bhas initiation and promotion assays to an *in vitro* screening for carcinogenesis, various PAHs and other initiators and promoters were evaluated by the assays; these could be classified into four groups (Table 2). Group I consists of chemicals showing positive results in the initiation assay but negative in the promotion assay. MNNG, MCA, AFB₁, and carcinogenic PAHs were classified in this group. Group II chemicals are negative in the initiation assay but positive in the promotion assay. Tumor promoters, TPA, LCA, and okadaic acid, are Group II chemicals. These promoters are also negative in bacterial mutation assays. Group III consists of chemicals showing positive response in both initiation and promotion assays (B[a]A, B[b]A, chrysene and perylene). Group IV consists of chemicals showing equivocal or negative response in both assays. These results showing that there are various kinds of PAHs with initiating and/or promoting activities suggest carcinogenic risk in mixtures of PAHs such as soot from exhaust gas, and particulate matter in polluted air.

In the present study, a metabolic activation system was not used in the examination of PAHs. Some chemi-

cals negative in the Bhas initiation assay (Groups II and IV) are positive in the bacterial reverse mutation assay in the presence of an exogenous metabolic activation system (Table 2). It is, therefore, necessary to include a metabolic activation system in the Bhas initiation assay. To incorporate the metabolic activation system into the Bhas assay, we tried to modify the present Bhas initiation assay. AFB₁, as a model initiator that requires metabolic activation by CYP enzymes such as 2A6, 3A4 and 1A2 [24,25], was used to validate the incorporation of the metabolic activation system. AFB₁ did not induce transformed foci in the initiation assay in the absence of the metabolic activation system but it induced transformed foci in its presence.

In summary, Bhas assays for the detection of both initiating and promoting activities of chemicals are more sensitive and economical than other cell transformation assays, and deserve consideration as a promising screening tool. However, the results obtained are still limited, and further studies are necessary to confirm the applicability of the Bhas assays especially in the presence of an exogenous metabolic activation system. In addition, the Bhas assays may be able to play an important role for understanding the mechanism of chemical carcinogenesis.

Acknowledgements

The study was supported through a grant of Long-range Research Initiative (LRI) by the Japan Chemical Industry Association (JCIA). The authors thank Dr. D.J. Fitzgerald for his precise reviewing.

References

- [1] I. Berenblum, The cocarcinogenic action of croton resin, *Cancer Res.* 1 (1941) 44–48.
- [2] W.F. Friedwald, P. Rous, The initiating and promoting elements in tumor production, *J. Exp. Med.* 80 (1944) 101–126.
- [3] M. Hollstein, J. McCann, F.A. Angelosanto, W.W. Nichols, Short-term tests for carcinogens and mutagens, *Mutat. Res.* 65 (1979) 133–226.
- [4] J. Ashby, R.W. Tennant, Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/NTP, *Mutat. Res.* 204 (1988) 17–115.
- [5] D.J. Fitzgerald, C. Piccoli, H. Yamasaki, Detection of non-genotoxic carcinogens in the BALB/c 3T3 cell transformation/mutation assay system, *Mutagenesis* 4 (1989) 286–291.
- [6] D.J. Fitzgerald, H. Yamasaki, Tumor promotion: models and assay systems, *Teratog. Carcinog. Mutagen.* 10 (1990) 89–102.
- [7] T. Kakunaga, A quantitative system for assay of malignant transformation by chemical carcinogens using a clone derived from BALB-3T3, *Int. J. Cancer* 12 (1973) 463–473.

- [8] T. Kakunaga, J.D. Crow, Cell variants showing differential susceptibility to ultraviolet light-induced transformation, *Science* 209 (1980) 505–507.
- [9] C.A. Reznikoff, D.W. Brankow, C. Heidelberger, Establishment and characterization of a cloned line of C3H mouse embryo cells sensitive to postconfluence inhibition of division, *Cancer Res.* 33 (1973) 3231–3238.
- [10] C.A. Reznikoff, J.S. Bertram, D.W. Brankow, C. Heidelberger, Quantitative and qualitative studies of chemical transformation of cloned C3H mouse embryo cells sensitive to postconfluence inhibition of cell division, *Cancer Res.* 33 (1973) 3239–3249.
- [11] A.L. Meyer, In vitro transformation assays for chemical carcinogens, *Mutat. Res.* 15 (1983) 323–338.
- [12] J.C. Barrett, T.W. Hesterberg, D.G. Thomassen, Use of cell transformation systems for carcinogenicity testing and mechanistic studies of carcinogenesis, *Pharmacol. Rev.* 36 (2 Suppl) (1984) 53S–70S.
- [13] S. Mondal, D.W. Brankow, C. Heidelberger, Two-stage chemical oncogenesis in cultures of C3H/10T1/2 cells, *Cancer Res.* 36 (1976) 2254–2260.
- [14] C. Boreiko, S. Mondal, K.S. Narayan, C. Heidelberger, Effect of 12-*O*-tetradecanoylphorbol-13-acetate on the morphology and growth of C3H/10T1/2 mouse embryo cells, *Cancer Res.* 40 (1980) 4709–4716.
- [15] IARC/NCI/EPA Working Group, Cellular and molecular mechanisms of cell transformation and standardization of transformation assays of established cell lines for prediction of carcinogenic chemicals: Overview and recommended protocols, *Cancer Res.* 45 (1985) 2395–2399.
- [16] K. Ohmori, K. Sasaki, S. Asada, N. Tanaka, M. Umeda, An assay method for the prediction of tumor promoting potential of chemicals by the use of Bhas 42 cells, *Mutat. Res.* 557 (2004) 191–202.
- [17] K. Sasaki, H. Mizusawa, M. Ishidate, Isolation and characterization of *ras*-transfected BALB/3T3 clone showing morphological transformation by 12-*O*-tetradecanoyl-phorbol-13-acetate, *Jpn. J. Cancer Res.* 79 (1988) 921–930.
- [18] K. Sasaki, H. Mizusawa, M. Ishidate, N. Tanaka, Establishment of a highly reproducible transformation assay of a *ras*-transfected BALB 3T3 clone by treatment with promoters, *Basic Life Sci.* 52 (1990) 411–416.
- [19] T. Kakunaga, The role of cell division in the malignant transformation of mouse cells treated with 3-methylcholanthrene, *Cancer Res.* 35 (1975) 1637–1642.
- [20] A. Fernandez, S. Mondal, C. Heidelberger, Probabilistic view of the transformation of cultured C3H/10T1/2 mouse embryo fibroblasts by 3-methylcholanthrene, *Proc. Natl. Acad. Sci. USA* 77 (1980) 7272–7276.
- [21] W.K. Lutz, Dose-response relationships in chemical carcinogenesis: superposition of different mechanisms of action, resulting in linear-nonlinear curves, practical thresholds, J-shapes, *Mutat. Res.* 405 (1998) 117–124.
- [22] K. Saotome, H. Morita, M. Umeda, Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drug, *Toxic. In Vitro* 3 (1989) 317–321.
- [23] T. Tsuchiya, M. Umeda, H. Nishiyama, I. Yoshimura, S. Ajimi, M. Asakura, H. Baba, Y. Dewa, Y. Ebe, Y. Fushiwaki, S. Hamada, T. Hamamura, M. Hayashi, Y. Iwase, Y. Kajiwara, Y. Kasahara, M. Kawabata, E. Kitada, K. Kudo, K. Mashiko, D. Miura, F. Mizuhashi, F. Mizuno, M. Nakajima, Y. Nakamura, N. Nobe, T. Oishi, E. Ota, A. Sakai, M. Sato, S. Shimada, T. Sugiyama, C. Takahashi, Y. Takeda, N. Tanaka, C. Toyozumi, T. Tsutsui, S. Wakuri, S. Yajima, N. Yajima, An interlaboratory validation study of the improved transformation assay employing BALB/c 3T3 cell: results of a collaborative study on the two-stage cell transformation assay by the non-genotoxic carcinogen study group, *ATRA* 27 (1999) 685–702.
- [24] J.M. Essigmann, R.G. Croy, R.A. Bennett, G.N. Wogan, Metabolic activation of aflatoxin B₁: patterns of DNA adduct formation, removal, and excretion in relation to carcinogenesis, *Drug Metab. Rev.* 13 (1982) 581–602.
- [25] F.P. Guengerich, T. Shimada, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes, *Chem. Res. Toxicol.* 4 (1991) 391–407.
- [26] S. Mondal, C. Heidelberger, Transformation of C3H/10T1/2CL8 mouse embryo fibroblasts by ultraviolet irradiation and a phorbol ester, *Nature* 260 (1976) 710–711.
- [27] C. Lasne, A. Gentil, I. Chouroulinkov, Two-stage carcinogenesis with rat embryo cells in tissue culture, *Br. J. Cancer* 35 (1977) 722–729.
- [28] L. Diamond, T. O'Brien, G. Rovera, Tumor promoters: effects on proliferation and differentiation of cells in culture, *Life Sci.* 23 (1978) 1979–1988.
- [29] N. Kaibara, E. Yurugi, S. Koga, Promoting effect of bile acids on the chemical transformation of C3H/10T1/2 fibroblasts in vitro, *Cancer Res.* 44 (1984) 5482–5485.
- [30] M. Suganuma, H. Fujiki, H. Suguri, S. Yoshizawa, M. Hirota, M. Nakayasu, M. Ojika, K. Wakamatsu, K. Yamada, T. Sugimura, Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter, *Proc. Natl. Acad. Sci. USA* 85 (1988) 1768–1771.
- [31] M. Umeda, K. Tanaka, T. Ono, Promotional effect of lithocholic acid and 3-hydroxyanthranilic acid on transformation of X-ray-initiated BALB/3T3 cells, *Carcinogenesis* 10 (1989) 1665–1668.
- [32] L.P. Yotti, C.C. Chang, J.E. Trosko, Elimination of metabolic cooperation in Chinese hamster cells by a tumor promoter, *Science* 206 (1979) 1089–1091.
- [33] A.W. Murray, D.J. Fitzgerald, Tumor promoters inhibit metabolic cooperation in cocultures of epidermal and 3T3 cells, *Biochem. Biophys. Res. Commun.* 91 (1979) 395–401.
- [34] M. Umeda, K. Noda, T. Ono, Inhibition of metabolic cooperation in Chinese hamster cells by various chemicals including tumor promoters, *Gann* 71 (1980) 614–620.
- [35] J.E. Trosko, R.J. Ruch, Cell-cell communication in carcinogenesis, *Frontiers Biosci.* 3 (1998) d208–d236.
- [36] T. Tsuchiya, M. Umeda, Relationship between exposure to TPA and appearance of transformed cells in MNNG-initiated transformation of BALB/c 3T3 cells, *Int. J. Cancer* 73 (1997) 271–276.
- [37] T. Sugimura, Multistep carcinogenesis: a 1992 perspective, *Science* 258 (1992) 603–607.
- [38] IARC, IARC Monographs on the evaluation of carcinogenic risks of chemicals to humans vol. 32, Polynuclear aromatic compounds, Part 1: Chemical, environmental and experimental data, IARC, Lyon, 1983.
- [39] IARC, IARC Monographs on the evaluation of carcinogenic risks to humans vol. 56: some naturally occurring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins IARC, Lyon, 1993.
- [40] IARC, IARC Monographs on the evaluation of carcinogenic risks to humans vol. 82: some traditional herbal medicines, some mycotoxins, naphthalene and styrene, IARC, Lyon, 2002.
- [41] M. Sakai, D. Yoshida, S. Mizusaki, Mutagenicity of polycyclic aromatic hydrocarbons and quinones on *Salmonella typhimurium* TA97, *Mutat. Res.* 156 (1985) 61–67.

- [42] J. McCann, E. Choi, E. Yamasaki, B.N. Ames, Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals, *Proc. Natl. Acad. Sci. USA* 72 (1975) 5135–5139.
- [43] K. Mossanda, F. Poncelet, A. Fouassin, M. Mercier, Detection of mutagenic polycyclic aromatic hydrocarbons in African smoked fish, *Food Cosmet. Toxicol.* 17 (1979) 141–143.
- [44] V.C. Dunkel, E. Zeiger, D. Brusick, E. McCoy, D. McGregor, K. Mortelmans, H.S. Rosenkranz, V.F. Simmon, Reproducibility of microbial mutagenicity assays. I. Tests with *Salmonella typhimurium* and *Escherichia coli* using a standardized protocol, *Environ. Mutagen.* 6 (Suppl. 2) (1984) 1–251.
- [45] T.J. Oberly, M.A. Rexroat, B.J. Bewsey, K.K. Richardson, K.C. Michaelis, An evaluation of the CHO/HGPRT mutation assay involving suspension cultures and soft agar cloning: results for 33 chemicals, *Environ. Mol. Mutagen.* 16 (1990) 260–271.
- [46] IARC, IARC Monographs on the evaluation of carcinogenic risks of chemicals to humans suppl. 7, Overall evaluation of carcinogenicity: an updating of IARC Monographs from vol. 1 to vol. 42, IARC, Lyon, 1987.
- [47] E. Zeiger, B. Anderson, S. Haworth, T. Lawlor, K. Mortelmans, *Salmonella* mutagenicity tests: IV. Results from the testing of 300 chemicals, *Environ. Mol. Mutagen.* 11 (Suppl 12) (1988) 1–157.
- [48] M. Diehl, F. Fort, Spiral Salmonella assay: validation against the standard pour-plate assay, *Environ. Mol. Mutagen.* 27 (1996) 227–236.
- [49] K. el-Bayoumy, S.S. Hecht, Mutagenicity of K-region derivatives of 1-nitropyrene; remarkable activity of 1- and 3-nitro-5H-phenanthro[4,5-*bcd*]pyran-5-one, *Mutat. Res.* 170 (1986) 31–40.
- [50] R.E. McMahon, J.C. Cline, C.Z. Thompson, Assay of 855 test chemicals in ten tester strains using a new modification of the Ames test for bacterial mutagens, *Cancer Res.* 39 (1979) 682–693.
- [51] R. Pahlman, Mutagenicity of naphthacene, a non-bay-region aromatic hydrocarbon, in *Salmonella*, *Mutat. Res.* 207 (1988) 205–212.
- [52] M.R. O'Donovan, The comparative responses of *Salmonella typhimurium* TA1537 and TA97a to a range of reference mutagens and novel compounds, *Mutagenesis* 5 (1990) 267–274.
- [53] F. Oesch, P. Bentley, H.R. Glatt, Prevention of benzo[*a*]pyrene-induced mutagenicity by homogeneous epoxide hydratase, *Int. J. Cancer* 18 (1976) 448–452.
- [54] S. Aonuma, T. Ushijima, M. Nakayasu, H. Shima, T. Sugimura, M. Nagao, Mutation induction by okadaic acid, a protein phosphatase inhibitor, in CHL cells, but not in *S. typhimurium*, *Mutat. Res.* 250 (1991) 375–381.
- [55] M.O. Bradley, B. Bhuyan, M.C. Francis, R. Langenbach, A. Peterson, E. Huberman, Mutagenesis by chemical agents in V79 Chinese hamster cells: a review and analysis of the literature. A report of the Gene-Tox Program, *Mutat. Res.* 87 (1981) 81–142.
- [56] C.G. Rogers, C. Heroux-Metcalf, I. Langlois, Evaluation of cytotoxicity and genotoxicity of okadaic acid, a non-phorbol ester type tumor promoter, in V79 Chinese hamster lung cells, *Toxicol. In Vitro* 8 (1994) 269–276.
- [57] B.S. Hass, R.H. Heflich, H.M. Schol, M.W. Chou, P.P. Fu, D.A. Casciano, Mutagenicity of the mononitrobenzo[*a*]pyrenes in Chinese hamster ovary cells mediated by rat hepatocytes or liver S9, *Carcinogenesis* 7 (1986) 681–684.
- [58] E.K. Fifer, R.H. Heflich, Z. Djuric, P.C. Howard, F.A. Beland, Synthesis and mutagenicity of 1-nitro-6-nitrosopyrene and 1-nitro-8-nitrosopyrene, potential intermediates in the metabolic activation of 1,6- and 1,8-dinitropyrene, *Carcinogenesis* 7 (1986) 65–70.
- [59] K.B. Delclos, R.H. Heflich, Mutation induction and DNA adduct formation in Chinese hamster ovary cells treated with 6-nitrochrysene, 6-aminochrysene and their metabolites, *Mutat. Res.* 279 (1992) 153–164.
- [60] A.D. Mitchell, C.J. Rudd, W.J. Caspary, Evaluation of the L5178Y mouse lymphoma cell mutagenesis assay: intralaboratory results for sixty-three coded chemicals tested at SRI International, *Environ. Mol. Mutagen.* 12 (Suppl. 13) (1988) 37–101.
- [61] D. Clive, R. McCuen, J.F. Spector, C. Piper, K.H. Mavournin, Specific gene mutations in L5178Y cells in culture, *Mutat. Res.* 115 (1983) 225–251.
- [62] A. Sakai, Y. Iwase, Y. Nakamura, K. Sasaki, N. Tanaka, M. Umeda, Use of a cell transformation assay with established cell lines, and a metabolic cooperation assay with V79 cells for the detection of tumor promoters: a review, *ATLA* 30 (2002) 33–59.

Practical threshold for micronucleated reticulocyte induction observed for low doses of mitomycin C, Ara-C and colchicine

Norihide Asano*, Dorothea K. Torous¹,
Carol R. Tometsko¹, Stephen D. Dertinger¹,
Takeshi Morita² and Makoto Hayashi³

Toxicological Research Center, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki Osaka 567-8680, Japan, ¹Litron Laboratories, 200 Canal View Boulevard, Rochester, NY 14623, USA, ²Division of Safety Information on Drug, Food and Chemicals and ³Division of Genetics and Mutagenesis, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan

Micronucleus induction was studied for the DNA target clastogens mitomycin C (MMC) and 1- β -D-arabinofuransylosine (Ara-C), and also the non-DNA target aneugen colchicine (COL) in order to evaluate the dose–response relationship at very low dose levels. The acridine orange (AO) supravital staining method was used for microscopy and the anti-CD71-FITC based method was used for flow cytometric analysis. In the AO method, 2000 reticulocytes were analysed as commonly advised, but in the flow cytometric method, 2000, 20 000, 200 000 and 1 000 000 reticulocytes were analysed for each sample to increase the detecting power (i.e. sensitivity) of the assay. The present data show that increasing the number of cells scored increases the statistical power of the assay when the cell was considered as a statistical unit. Even so, statistically significant differences from respective vehicle controls were not observed at the lowest dose level for MMC and Ara-C, or the lower four dose levels for COL, even after one million cells were analysed. When the animal was considered as a statistical unit, only the top dose group for each chemical showed significant increase of micronucleated reticulocytes frequency. As non-linear dose–response curves were obtained for each of the three chemicals studied, these observations provide evidence for the existence of a practical threshold for the DNA target clastogens as well as the non-DNA target aneugen studied.

Introduction

As chemical safety evaluations are performed, the existence of a threshold is an important issue when considering genotoxic carcinogens. There are two important threshold concepts, i.e. ‘absolute’ threshold and ‘practical or biological’ threshold in genotoxicity. The ‘absolute’ threshold is defined as a concentration below which a cell would not ‘notice’ the presence of the chemical, and the ‘practical or biological’ one is considered as a concentration below which any effect is biologically unimportant (1–3). Some chemicals clearly exhibit a threshold, and non-DNA target mechanisms of action (e.g. spindle apparatus disturbance, topoisomerase II inhibition, DNA synthesis inhibition, overloading homeostatic defence, and physiological perturbation) provide rationale for the non-linear responses that

are observed (4). For instance, the spindle poison, colchicine (COL), damages spindle fibres, but the effect on chromosome movement should be detected only at the concentration that damages enough microtubules to impair the anchorage of the chromosome. This mechanism is thought to explain the threshold that is observed for this particular non-DNA target chemical (5). Up to the present, a widely held view is that genotoxic carcinogens do not have a threshold, and thus it has been difficult to determine the acceptable daily intake (ADI) safety exposure level. For this reason, such chemicals have been banned for use in daily life, most notably in food and food-related chemicals. Recently, however, discussion on the strategy for evaluating genotoxicity for risk assessment has been initiated (6–8). Moreover, in many cases and especially in the European Union, the principle of reducing exposure to unavoidable toxic compounds to levels that are as-low-as-reasonably-achievable (ALARA) has been advocated (9–11).

Adding to this complex discussion are reports by Fukushima and his group (12–14) who have demonstrated the existence of practical thresholds for the genotoxic hepatocarcinogens 2-amino-3, 8-dimethylimidazo [4,5-*f*] quinoxaline (MeIQx) and *N*-nitrosodiethylamine, and even hormesis for phenobarbital. These investigators studied carcinogenicity, glutathione *S*-transferase placental form (GSTP) positive focus, gene mutation, DNA oxidative damage and DNA adduct formation at very low dose levels. They showed GSTP positive focus induction at the dose level at which carcinogenicity could not be detected; gene mutation could be observed at the dose level at which GSTP positive foci could not be detected, and so on. Therefore, they concluded that at least practically, a threshold for carcinogenicity existed. It has been claimed that one of the shortcomings of their proposal is the lack of discussion of the sensitivity of the assays they performed, because, from a statistical view point, the power of the assay (i.e. sensitivity) largely depends on the number of cells analysed.

The micronucleus assay has been widely used for evaluating chemical genotoxicity *in vivo*. One of the characteristics of the rodent peripheral blood micronucleus assay is its simple endpoint, i.e. a small DNA containing cell inclusion in the cytoplasm of enucleated erythrocytes. Because of this simplicity, automation of analysis has been achieved by image analysis (15–17) and flow cytometry (18–23). We have developed a high performance manual method using acridine orange (AO) supravital staining (24,25). We have also developed a flow cytometric method utilizing an erythrocyte surface antigen for CD71 to identify young erythrocytes and the use of malaria infected erythrocytes as an instrument calibration standard for accurate measurement (21–23,26). In the present study, we aimed to show the dose–effect relationship of micronucleus inducers with different modes of action at extremely low dose levels. We applied two methods, i.e. the manual AO supravital staining method and flow cytometry, on three model

*To whom correspondence should be addressed. Tel: +81 (0) 72 621 0492; Fax: +81 (0) 72 621 0315; Email: asanonri@nitto.co.jp

chemicals: mitomycin C (MMC), which is a cross-linking agent and typical micronucleus inducer (27) frequently used as a positive control in the micronucleus assay; 1- β -D-arabino-furanosylcytosine (Ara-C), which is a long-patch repair inhibitor and known inducer of small micronuclei (28); and COL, a spindle poison that induces large micronuclei (29). Another aim was to evaluate the degree to which the statistical power of the assay depends on the number of target cells interrogated.

Further impetus to study low dose effects came from reports by Grawé *et al.* (30) and Abramsson-Zetterberg (31), who measured genotoxicant-induced micronuclei using an alternate, dual laser flow cytometric technique. We discuss the interpretation of very weak micronucleus induction, if any, at low dose levels and also the existence of a threshold effect.

Materials and methods

Chemical substances

Three micronucleus inducers with different modes of action, MMC (CAS number: 50-07-7), Ara-C (CAS number: 147-94-4), and COL (CAS number: 64-86-8) were obtained from Kyowa Hakko (Tokyo, Japan), Merck (PA, USA) and Sigma (Mo, USA), respectively. MMC was dissolved with sterile distilled water and COL and Ara-C were dissolved with physiological saline. Solvents were used as negative controls.

AO pre-coated slides for supravital staining were obtained from Toyobo Co., Osaka. Fixative, anticoagulant and other all materials necessary for diluting, fixing and shipping specimens for flow cytometric analysis were from Mouse MicroFlow[®] Basic Kits (transported from Litron Laboratories, NY).

Animals

Healthy seven-week-old male CD-1 mice (ICR, Charles River Japan Inc., Hino, Japan) with a mean body weight of 34.6 g were used after a week's acclimation. The mice were housed at $21 \pm 1^\circ\text{C}$ and $55 \pm 10\%$ relative humidity and exposed to 12-h light-dark cycle. Five mice per group were assigned randomly and were given commercial food pellets (CE-2, CLEA Japan Inc., Tokyo

Japan) and tap water *ad libitum* throughout the acclimation and the experimental period.

Micronucleus assay

The highest dose level of each chemical was determined experimentally or by referring to the published data (27,32-34). The objective was to choose a high dose level that induced micronuclei slightly, but statistically significantly. We selected 0.3 mg/kg for MMC, 6 mg/kg for Ara-C, and 0.8 mg/kg for COL as the high dose levels. The six dose levels for MMC and five dose levels for Ara-C and COL were spaced by the square root of 10. A solvent control was assigned to each experiment as reference. Each chemical was delivered intraperitoneally (10 ml/kg) once and blood was collected 48 h after treatment based on data from a previous paper (25). Treatment, sample preparation and AO scoring were performed at Nitto Denko, Osaka, Japan and fixed blood samples were sent by air on dry ice to Litron Laboratories, NY for flow cytometric analysis.

All AO supravital staining slides were coded and analysed without knowledge of treatment information. All tubes containing fixed blood cells for flow cytometric analysis were also coded. All codes were broken only after analysis was completed.

AO supravital staining micronucleus assay

The AO supravital staining micronucleus assay was performed according to the method of Hayashi *et al.* (24,25). Aliquots of 5 μl of peripheral blood, obtained from the tail blood vessel of each mouse, was put on an AO coated glass slide, and immediately covered with a glass coverslip. Two thousand reticulocytes were analysed by fluorescence microscopy (Model:AHBT3-RFC, Olympus, Tokyo Japan) with blue-excitation filter set, and the number of micronucleated reticulocytes (MNRET) was scored.

Flow cytometric analysis

At the same time of AO supravital sampling, another 100 μl blood was collected via orbital sinus into the Mouse MicroFlow[®] basic kit-supplied anticoagulant solution using a cleaned glass capillary. Each sample was fixed in duplicate with ultracold (-80°C) methanol, agitated vigorously and immediately placed at -80°C until shipment on dry ice from Nitto Denko to Litron Laboratories for flow cytometric analysis.

On the day of analysis, samples were washed out of fixative with ~ 12 ml Hank's Balanced Salt Solution (HBSS). A high-density/CD71-associated fluorescence thresholding technique was used (35,36). Briefly, with this method, 80 μl of each washed cell pellet was added to polypropylene tubes

Table I. Frequencies of micronucleated reticulocytes (%) assay by manual and flow analysis

Chemical	Dose (mg/kg body wt)	Number of cells analysed				
		Manual	Flow cytometry			
		2 K	2 K	20 K	200 K	1 M
MMC	0	0.22 \pm 0.06	0.23 \pm 0.16	0.25 \pm 0.09	0.23 \pm 0.06	0.23 \pm 0.05
	0.00095	0.33 \pm 0.06	0.17 \pm 0.04	0.21 \pm 0.05	0.24 \pm 0.06	0.24 \pm 0.05 ^a
	0.00300	0.24 \pm 0.08	0.25 \pm 0.11	0.27 \pm 0.05	0.25 \pm 0.05	0.25 \pm 0.05 ^b
	0.00948	0.24 \pm 0.17	0.22 \pm 0.09	0.28 \pm 0.04	0.27 \pm 0.03 ^b	0.27 \pm 0.04 ^b
	0.03000	0.20 \pm 0.06	0.22 \pm 0.08	0.24 \pm 0.08	0.19 \pm 0.08	0.23 \pm 0.08
	0.09480	0.35 \pm 0.14	0.27 \pm 0.10	0.25 \pm 0.08	0.28 \pm 0.07 ^b	0.27 \pm 0.06 ^b
Ara-C	0.30000	0.64 \pm 0.15 ^{d,b}	0.36 \pm 0.10	0.40 \pm 0.11 ^{e,b}	0.41 \pm 0.06 ^{d,b}	0.39 \pm 0.05 ^{d,b}
	0.000	0.32 \pm 0.10	0.21 \pm 0.05	0.21 \pm 0.05	0.23 \pm 0.04	0.22 \pm 0.02
	0.060	0.26 \pm 0.15	0.19 \pm 0.07	0.24 \pm 0.07	0.24 \pm 0.07	0.24 \pm 0.07
	0.190	0.28 \pm 0.18	0.30 \pm 0.06	0.23 \pm 0.06	0.25 \pm 0.04 ^c	0.25 \pm 0.03 ^c
	0.600	0.32 \pm 0.03	0.21 \pm 0.13	0.25 \pm 0.05	0.27 \pm 0.05 ^b	0.27 \pm 0.05 ^b
	1.890	0.42 \pm 0.21	0.24 \pm 0.11	0.29 \pm 0.07 ^b	0.29 \pm 0.05 ^b	0.28 \pm 0.04 ^b
COL	6.000	0.81 \pm 0.38 ^{d,b}	0.34 \pm 0.10 ^d	0.41 \pm 0.11 ^{e,b}	0.39 \pm 0.09 ^{e,b}	0.39 \pm 0.09 ^{e,b}
	0.00000	0.32 \pm 0.08	0.22 \pm 0.10	0.25 \pm 0.05	0.27 \pm 0.05	0.28 \pm 0.06
	0.00800	0.18 \pm 0.11	0.21 \pm 0.09	0.22 \pm 0.06	0.22 \pm 0.04	0.22 \pm 0.03
	0.02520	0.31 \pm 0.13	0.16 \pm 0.09	0.20 \pm 0.04	0.22 \pm 0.04	0.21 \pm 0.04
	0.08000	0.13 \pm 0.08	0.22 \pm 0.11	0.23 \pm 0.06	0.21 \pm 0.05	0.21 \pm 0.03
	0.25200	0.34 \pm 0.19	0.21 \pm 0.08	0.28 \pm 0.05	0.26 \pm 0.04	0.27 \pm 0.05
0.80000	0.56 \pm 0.19 ^{b,d}	0.41 \pm 0.14	0.41 \pm 0.13 ^b	0.44 \pm 0.13 ^b	0.44 \pm 0.13 ^b	

Data are shown as mean \pm SD (%) of five mice.

^aOnly 881 389 instead of 1 M cells were analysed in one of five mice.

^bFisher's exact test (all groups) significant difference at 1%.

^cFisher's exact test (all groups) significant difference at 5%; no mark, not significant.

^dStudent's *t*-test (20 and 200 K, and 1 M groups) significant difference at 1%.

^eStudent's *t*-test (20 and 200 K, and 1 M groups) significant difference at 5%.

containing 80 µl RNase/antibodies (1.0 ml HBSS, 10 µl anti-CD71-FITC, 5 µl anti-CD61-PE and RNase A at 5 mg/ml). Antibodies, and all other flow cytometry reagents, including fixed malaria-infected rodent blood (malaria biostandard), were from Mouse MicroFlowPLUS® Kits (available from Litron Laboratories, Rochester, NY, and BD Biosciences-Pharmingen).

Following successive 30-min incubations at 4°C and ~37°C, the cells were placed at 4°C until analysis (same day). For analysis, each sample was resuspended in approximately 1.5 ml propidium iodide (PI) staining solution. Of the stained blood sample 100 µl was transferred to a separate tube containing 400 µl PI. This diluted sample was used to determine the percentages of reticulocytes and micronucleated normochromatic erythrocyte (MN-NCE) of each blood sample by the analysis of 1 000 000 (1 M) total erythrocytes.

The corresponding undiluted sample was then analysed using the CD71-thresholding technique whereby CD71-negative erythrocytes (the majority of the cells) were omitted from acquisition (35,36). The frequency of micronuclei was then measured for each sample using each of the following stop modes: 2000 (2 K), 18 000 (18 K), 180 000 (180 K) and 800 000 (800 K) reticulocytes. By adding the successive values, percentage of MNRET frequencies could be calculated based on the analysis of 2 K, 20 000 (20 K), 200 000 (200 K) and 1 M reticulocytes.

Statistical analysis

P-values for each comparison with respective controls were calculated by Fisher's exact method. For the flow cytometry data based on 20 K or more cells analysed, a Student's *t*-test was used after normality of the data was confirmed. When determining statistical significance, a Bonferroni correction was used to adjust for the multiple (i.e. 5) comparisons made.

Results

The group means of five mice/group are summarized in Table I for the AO supravital staining method based on the observation of 2 K reticulocytes and for the flow cytometric method based on the observation of 2, 20 and 200 K, and 1 M reticulocytes. The *P*-values for all three chemicals were <0.01 at the highest dose group when the Fisher's exact test was applied. However, when considering individual differences, this was not the case for all COL high dose datasets when evaluated using the Student's *t*-test. Dose-response relationship curves of MMC, Ara-C and COL are shown in Figure 1. Dose-response curves of each chemical were similar between AO supravital analysis and flow cytometric analysis, although there was a tendency for the absolute values of induced MNRET to be higher by the AO supravital method than by the flow cytometric method, especially at higher dose levels.

It is evident that the variation among mice in each dose group decreased depending on the number of cells analysed. Even so, individual differences among animals in each group were observed even when 1 M reticulocytes were scored per sample. Likewise, the smoothness of the dose-response curves tended to increase as the number of cells analysed increased. As a representative example, Figure 2 shows individual scattergrams of MMC at 2, 20 and 200 K, and 1 M reticulocytes analysed. There are not, however, essential differences among results based on the number of cells analysed.

Discussion

According to the present data, MNRET frequencies obtained using the AO supravital staining method tended to be higher than those by flow cytometric analysis. This phenomenon may be explained by modest differences in the age cohort of reticulocytes analysed by each method, i.e. AO supravital staining, where the analysis is restricted to Types I, II and III reticulocytes, and the flow cytometric method, where the analysis was restricted to reticulocytes with the CD71-positive phenotype. In both analysis procedures, the method of defining reticulocytes was kept consistent for all samples.




Fig. 1. Dose-response curves for MMC, Ara-C and COL. Each symbol shows individual number of micronucleated reticulocytes. In each dose group, a colour shows identical mouse for each experimental size for flow cytometry (closed symbol) and manual analysis (open symbols).

For flow cytometry, our data show that 20 and 200 K were sufficient to obtain reliable data for the evaluation of micronucleus induction. While flow cytometric data associated with analysis of 2 K reticulocytes were slightly more variable than corresponding microscopy-based measurements, automated acquisition of 20 K reticulocytes yielded essentially equivalent power of detection compared to the AO method. When 200 K and 1 M reticulocytes were analysed per specimen, assay sensitivity was observed to improve significantly, as evidenced by the lower doses at which statistical significance was noted when evaluated by Fisher's exact test. This was true when cells were the statistical unit evaluated, but not when individual mice were considered to be the unit. This issue is discussed




Fig. 2. Frequencies of micronucleated reticulocytes (%) for MMC based on 2, 20 and 200 K, and 1 M for flow cytometry and 2 K for manual microscopy. Each symbol shows the frequency of one mouse with exceptions because of overlapping (five animals per group).

in a companion paper wherein data from a reconstruction experiment are presented (37). In that study it was observed that when 200 K or 1 M cells per sample were analysed, the scoring error decreased and converged to a respective value. However, in the present study, the differences among the individual animals became apparent and there was more data variability within each dose group.

Grawé *et al.* (30) reported low dose effects on MMC, diepoxybutane, cyclophosphamide and COL using flow cytometry (stained with Hoechst 33342 for DNA and thiazole orange for RNA). Generally, one animal per dose level was used and 200 K polychromatic erythrocytes were analysed. Our present data agree with the COL data showing a non-linear dose-response, but in contrast to our present results, they showed linear dose-response relationships for extremely low dose levels of MMC, 0.007 mg/kg; diepoxybutane, 0.44 mg/kg; and cyclophosphamide, 0.3 mg/kg. Abramsson-Zetterberg *et al.* (31) also showed linear dose-response curves for acrylamide down to very low dose levels (1 mg/kg body wt) and observed no threshold. Although we did not evaluate acrylamide as a model chemical in this study, we did not observe linear dose-response curves, even for MMC and Ara-C, which are DNA-reactive clastogens. We could not find any rationale to explain such differences at the present time, and believe it is necessary to continue studying chemicals that interact directly with DNA to better understand their effect at extremely low dose levels.

To confirm biological and statistical relevance of the present study data, we performed a reconstruction model experiment using serial dilutions of malaria-infected blood with non-treated mouse blood (37). The samples were analysed by flow

Table II. Individual data in the Ara-C study by flow cytometry analysed 1 M cells

Mouse ID	Dose (mg/kg body wt)					
	0.00	0.06	0.19	0.60	1.89	6.00
1	0.24	0.26	0.25	0.28	0.34	0.39
2	0.21	0.32	0.30	0.31	0.24	0.31
3	0.19	0.16	0.23	0.31	0.27	0.50
4	0.25	0.28	0.21	0.18	0.24	0.46
5	0.22	0.16	0.24	0.25	0.29	0.29
Mean	0.22	0.24	0.25	0.27	0.28	0.39
SD	0.02	0.07	0.03	0.05	0.04	0.09

cytometry based on 2, 20 and 200 K (Experiment 1) and up to 1 M (Experiment 2) cells. These data show extremely high performance of the flow cytometric assay in terms of accuracy, especially when 200 K or more reticulocytes are evaluated per specimen. This result shows that the statistical power of the assay depended on the number of analysed cells. This dilution experiment supports our conclusion that thresholds were present for micronucleus induction in reticulocytes for the three model chemicals analysed at very low dose levels.

It might be difficult to prove the existence of thresholds in toxicology or biology in general using statistical methods (38), and it is not easy to discuss the threshold concept from the biological viewpoint. However, when we only consider mean values, for example in the case of Ara-C, the MNRET frequencies appeared to increase linearly, but when the individual values (Table II) were evaluated, the differences among




Fig. 3. Dose-response curves of MMC, Ara-C and COL in wider range of dose levels superimposed to the present data with the results of our published data. MMC: Hara *et al.*, 1992 (Table I) Study 1, 48 h; Ara-C: Iwakura *et al.*, 1992 (Table I) Laboratory B, 48 h; COL: Kondo *et al.*, 1992 (Table I) Laboratory 4, 48 h.

animals became clearer. Two individuals at the lowest dose group (mouse ID 3 and 5) demonstrated the lowest MNRET frequency (0.16%) even when including the vehicle control group. The control data variation in the Ara-C experiment was less than that in the MMC or COL experiments. When the Student's *t*-test was applied to the data obtained by flow cytometry based on the analysis of ≥ 20 K cells, only the highest dose groups were significantly different from the concurrent control for MMC and Ara-C. Therefore, we should consider the individual animal differences to determine the micronucleus induction ability of the chemical being studied. It is likely that at very low doses of genotoxicant, as were studied here, individual differences in DNA repair activity, metabolism related cytochrome P450 activity, or anti-oxidant concentration etc. play a larger role in dictating the micronucleus incidence of each individual of an exposure group.

In addition, Figure 3 shows the dose-response curves of these three model chemicals in a wider range of dose levels superimposed on the results of published data (27,32,34) using the same strain of mouse and same manner of experiments by AO supravital staining. Closed circles represent the data from the present study and open circles are published data for higher dose levels. The dose-response curves became clearer by adding the data from higher dose levels and the practical threshold or the threshold were shown. Moreover, COL even shows the

tendency of inhibition in induction of micronuclei at extremely low dose levels (U- or J-shape response). Hormesis usually implies increased repair capability or some other protective, adaptive response in the field of radiobiology (1). The COL data presented herein is suggestive of a hormesis-like effect, and further work aimed at elucidating the mechanisms and significance of this observation is warranted.

Considering the data detailed above, an important conclusion is the existence of a biological or practical threshold in the genotoxicity assay on DNA target chemicals as well as non-target chemicals. Although we used only three model chemicals in the present study, we could draw the following conclusions: (i) the flow cytometric micronucleus assay method is a powerful tool when ≥ 20 K cells were analysed; (ii) the AO supravital staining micronucleus assay method and the flow cytometric method gave qualitatively similar results; (iii) when the cell is considered the statistical unit and more cells are analysed, both power and assay sensitivity at lower dose levels is significantly enhanced as evidenced by the significant differences observed when compared to vehicle control; and (iv) non-linear dose-response curves were obtained for the model chemicals studied here when evaluating the individual animal as a unit, suggesting the existence of a practical threshold for the DNA target micronucleus inducers (MMC and Ara-C) as well as the non-DNA target chemical (COL).

Acknowledgement

This work supported by the Health and Labor Sciences Research Grants (H15-Food-008).

References

- Lutz, W.K. (1998) Dose-response relationships in chemical carcinogenesis: superposition of different mechanisms of action, resulting in linear-nonlinear curves, practical thresholds, J-shapes. *Mutat. Res.*, **405**, 117-124.
- Kirsch-Volders, M., Aardema, M.J. and Elhajouji, A. (2003) Concepts of threshold in mutagenesis and carcinogenesis. *Mutat. Res.*, **464**, 3-11.
- Lynch, A., Harvey, J., Aylott, M., Nicholas, E., Burman, S., Walker, S. and Rees, R. (2003) Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity. *Mutagenesis*, **18**, 345-353.
- Henderson, L., Albertini, S. and Aardema, M.J. (2000) Thresholds in genotoxicity response. *Mutat. Res.*, **464**, 123-128.
- Elhajouji, A., Hummelen, P.V. and Kirsch-Volders, M. (1995) Indications for a threshold of chemically-induced aneuploidy *in vitro* in human lymphocytes. *Environ. Mol. Mutagen.*, **26**, 292-304.
- Committee on mutagenicity of chemicals in food, consumer products and the environment (COM) (2000) *Guidance on a Strategy for Testing of Chemicals for Mutagenicity*, Department of Health, UK, December 2000.
- Dearfield, K.L., Cimino, M.C., McCarroll, N.E., Maurer, I. and Valcovic, L.R. (2002) Genotoxicity risk assessment: a proposed classification strategy. *Mutat. Res.*, **521**, 121-135.
- Müller, L., Blakey, D., Dearfield, K.L. *et al.* (2003) Strategy for genotoxicity testing and stratification of genotoxicity test results—report on initial activities of the IWGT Expert Group. *Mutat. Res.*, **540**, 177-181.
- Bolt, H.M., Foth, H., Hengstler, J.G. and Degen, G.H. (2004) Carcinogenicity categorization of chemicals—new aspects to be considered in a European perspective. *Toxicol. Lett.*, **151**, 29-41.
- Bolt, H.M. and Degen, G.H. (2004) Human carcinogenic risk evaluation, Part II: Contributions of the EUROTOX specialty section for carcinogenesis. *Toxicol. Sci.*, **81**, 3-6.
- Streffer, C., Bolt, M.H., Føllesdal, D., Hall, P., Hengstler, J.G., Jakob, P., Oughton, D., Prieß, E., Rehbindler, E. and Swanton, E. (2004) *Low Dose Exposures in The Environment, Dose-Effect Relations and Risk Evaluation*, Springer-Verlag, Berlin
- Fukushima, S., Waniuchi, H., Morimura, K., Wei, M., Nakae, D., Konishi, Y. *et al.* (2002) Lack of a dose-response relationship for carcinogenicity in the rat liver with low doses of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline or *N*-nitrosodiethylamine. *Jpn. J. Cancer Res.*, **93**, 1076-1082.

13. Fukushima,S., Wanibuchi,H., Morimura,K. *et al.* (2003) Lack of initiation activity in rat liver of low doses of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline. *Cancer Lett.*, **191**, 35–40.
14. Kinoshita,A., Wanibuchi,H., Morimura,K., Wei,M., Shen,J., Imaoka,S., Funae,Y. and Fukushima,S. (2003) Phenobarbital at low dose exerts hormesis in rat hepatocarcinogenesis by reducing oxidative DNA damage, altering cell proliferation, apoptosis and gene expression. *Carcinogenesis*, **24**, 1389–1399.
15. Romagna,F. and Staniforth,C.D. (1989) The automated bone marrow micronucleus test. *Mutat. Res.*, **213**, 91–104.
16. Tates,A.D., van Welie,M.T. and Ploem,J.S. (1990) The present state of the automated micronucleus test for lymphocytes. *Int. J. Radiat. Biol.*, **58**, 813–825.
17. Asano,N., Katsuma,Y., Tamura,H., Higashikuni,N. and Hayashi,M. (1998) An automated new technique for scoring the rodent micronucleus assay: computerized image analysis of acridine orange supravivally stained peripheral blood cells. *Mutat. Res.*, **404**, 149–154.
18. Hayashi,M., Norppa,H., Sofuni,T. and Ishidate,M. Jr (1992) Mouse bone marrow micronucleus test using flow cytometry. *Mutagenesis*, **7**, 251–256.
19. Hayashi,M., Norppa,H., Sofuni,T. and Ishidate,M. Jr. (1992) Flow cytometric micronucleus test with mouse peripheral erythrocytes. *Mutagenesis*, **7**, 257–264.
20. Grawé,J., Zetterberg,G. and Amnéus,H. (1992) Flow-cytometric enumeration of micronucleated polychromatic erythrocytes in mouse peripheral blood. *Cytometry*, **13**, 750–758.
21. Tometsko,A.M., Torous,D.K. and Dertinger,S.D. (1993) Analysis of micronucleated cells by flow cytometry. 1. Achieving high resolution with a malaria model. *Mutat. Res.*, **292**, 129–135.
22. Dertinger,S.D., Torous,D.K. and Tometsko,K.R. (1996) Simple and reliable enumeration of micronucleated reticulocytes with a single-laser flow cytometer. *Mutat. Res.*, **371**, 283–292.
23. Torous,D., Dertinger,S., Hall,N. and Tometsko,C. (2000) Enumeration of micronucleated reticulocytes in rat peripheral blood: a flow cytometric study. *Mutat. Res.*, **465**, 91–99.
24. Hayashi,M., Morita,T., Kodama,Y., Sofuni,T. and Ishidate,M. Jr (1990) The micronucleus assay with mouse peripheral blood reticulocytes using acridine orange coated slides. *Mutat. Res.*, **245**, 245–249.
25. CSGMT (The Collaborative Study Group for the Micronucleus Test). (1992) Micronucleus test with mouse peripheral blood erythrocytes by acridine orange supravital staining: The summary report of the 5th collaborative study by CSGMT/JEMSEMMMS. *Mutat. Res.*, **278**, 83–98.
26. Dertinger,S.D., Torous,D.K., Hall,N.E., Tometsko,C.R. and Gasiewicz,T.A. (2000) Malaria-infected erythrocytes serve as biological standards to ensure reliable and consistent scoring of micronucleated erythrocytes by flow cytometry. *Mutat. Res.*, **464**, 195–200.
27. Hara,M., Nakagawa,S., Fujioka,E., Ayukawa,E. and Izushi,T. (1992) Detection of micronuclei in peripheral blood of mitomycin C-treated mice using supravital staining with acridine orange. *Mutat. Res.*, **278**, 175–179.
28. Hayashi,M., Sofuni,T. and Ishidate,M. Jr (1984) Kinetics of micronucleus formation in relation to chromosomal aberrations in mouse bone marrow. *Mutat. Res.*, **127**, 129–137.
29. Yamamoto,K.I. and Kikuchi,Y. (1980) A comparison of diameters of micronuclei induced by clastogens and by spindle poisons. *Mutat. Res.*, **71**, 127–131.
30. Grawé,J., Abramsson-Zetterberg,L. and Zetterberg,G. (1998) Low dose effects of chemicals as assessed by the flow cytometric *in vivo* micronucleus assay. *Mutat. Res.*, **405**, 199–208.
31. Abramsson-Zetterberg,L. (2003) The dose–response relationship at very low doses of acrylamide is linear in the flow cytometer-based mouse micronucleus assay. *Mutat. Res.*, **535**, 215–222.
32. Iwakura,K., Tamura,H., Matsumoto,A., Ajimi,S., Ogura,S., Kakimoto,K., Matsumoto,T. and Hayashi,M. (1992) The micronucleus assay with peripheral blood reticulocytes by acridine orange supravital staining with 1-beta-D-arabinofuranosyl cytosine. *Mutat. Res.*, **278**, 131–137.
33. Asano,N., Morita,T. and Watanabe,Y. (1989) Micronucleus test with colchicine given by intraperitoneal injection and oral gavage. *Mutat. Res.*, **223**, 391–394.
34. Kondo,Y., Honda,S., Nakajima,M., Miyahana,K., Hayashi,M., Shinagawa,Y., Sato,S., Inoue,K., Nito,S. and Ariyuki,F. (1992) Micronucleus test with vincristine sulfate and colchicine in peripheral blood reticulocytes of mice using acridine orange supravital staining. *Mutat. Res.*, **278**, 187–191.
35. Dertinger,S.D., Campausen,K., MacGregor,J.T. *et al.* (2004) Three-color labeling method for flow cytometric measurement of cytogenetic damage in rodent and human blood. *Environ. Mol. Mutagen.*, **44**, 427–435.
36. Torous,D.K., Hall,N.E., Illi-Love,A.H. *et al.* (2005) Interlaboratory validation of a CD71-based flow cytometric method (Microflow) for the scoring of micronucleated reticulocytes in mouse peripheral blood. *Environ. Mol. Mutagen.*, **45**, 44–55.
37. Torous,D., Asano,N., Tometsko,C., Sugunan,S., Dertinger,S., Morita,T. and Hayashi,M. (2005) Performance of flow cytometric analysis for the micronucleus assay—a reconstruction model using serial dilutions of malaria infected cells with normal mouse peripheral blood. *Mutagenesis*, **21**, 11–13.
38. Edler,L. and Kopp-Schnider,A. (1998) Statistical models for dose exposure. *Mutat. Res.*, **405**, 227–236.

Received on May 24, 2005; revised on October 27, 2005;
accepted on November 15, 2005

4-Oxo-2-hexenal, a Mutagen Formed by ω -3 Fat Peroxidation, Causes DNA Adduct Formation in Mouse Organs

Hiroshi KASAI^{1*}, Muneyuki MAEKAWA^{1,2}, Kazuaki KAWAI¹, Kenji HACHISUKA²,
Yoshikazu TAKAHASHI³, Hikaru NAKAMURA³, Ryuichi SAWA³,
Saburo MATSUI⁴ and Tomonari MATSUDA⁴

¹ Department of Environmental Oncology, Institute of Industrial Ecological Sciences;

² Department of Rehabilitation Medicine; University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

³ Microbial Chemistry Research Center, 3-14-23, Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan

⁴ Department of Technology and Ecology, Graduate School of Global Environmental Studies, Kyoto University, Sakyo, Kyoto 606-8501, Japan

Received March 28, 2005 and accepted August 29, 2005

Abstract: To identify mutagens formed in a model reaction of lipid peroxidation, linolenic acid methyl ester and hemin were reacted with dG. As a result, a 4-oxo-2-hexenal-dG adduct (dG*) was identified in the model reaction mixture. The 4-oxo-2-hexenal (4-OHE) showed mutagenic activity in the *Salmonella typhimurium* strains TA100 and TA104. After 4-OHE was orally administered to mice, dG*, 4-OHE-dC- and 4-OHE-5-methyl-dC adducts were detected in esophageal, stomach and intestinal DNA. In the vapor phase released from the methyl linolenate-hemin model system, and in the smoke released during the broiling of fish, 4-OHE was detected by GCMS. The 4-OHE seems to be produced by the auto-oxidation of ω -3 polyunsaturated fatty acids. These results provide a warning to workers dealing with ω -3 fats, who may be exposed to this volatile mutagen.

Key words: 4-oxo-2-hexenal, ω -3 polyunsaturated fatty acids, DNA adduct

It is important to identify environmental mutagens and to remove them to prevent cancer in industry workers. We have been interested in the mutagens produced by lipid peroxidation^{1,2)}, because they may be formed during the extraction and purification of edible oils, or by frying foods with vegetable-oil. Many low molecular-weight mutagens are released into the atmosphere by oil factories, the food industry, and restaurant kitchens. Various lipid peroxide compounds are produced by the oxidative fragmentation of fats catalyzed by iron and heat or light. Our study focused on the identification of mutagens in the lipid peroxide products formed from ω -3 polyunsaturated fatty acids, such

as linolenic acid.

It is well known that many mutagens react with DNA components, particularly with deoxyguanosine (dG)³⁾. To identify the mutagens formed in a model reaction of lipid peroxidation, linolenic acid methyl ester and hemin were reacted with dG in phosphate buffer (pH 7.4), as an emulsion for 72 h at 20°C. The dG-mutagen adducts were isolated by HPLC, and their structures were determined by mass-, UV-, ¹H- and ¹³C-NMR spectra. As a result, the 4-oxo-2-hexenal-dG adduct (dG*) was identified in the model reaction mixture. M+Na, m/e 384.1256 (384.1284 calcd. for C₁₆H₁₉N₅NaO₅); UV λ max in H₂O, 228, 280 nm. The structure was confirmed by comparison with an authentic dG* sample prepared from synthetic 4-oxo-2-hexenal (4-

*To whom correspondence should be addressed.




Fig. 1. Structures of DNA adducts formed by 4-oxo-2-hexenal.

OHE) and dG, and by X-ray crystallography of the 4-OHE-9-ethylguanine-adduct. The 4-OHE was mutagenic in the *Salmonella* strains, TA100 and TA104, without S9 mix. Its specific mutagenic activities against TA100 and TA104 were 78 and 67 revertants/ μg , respectively. The mutagenicity of 4-OHE has not been reported thus far. It also induced apoptosis in human HL-60 cells. This is reasonable because DNA damage is a common trigger for apoptosis induction in mammalian cells⁴).

The 4-OHE reacts not only with dG but also with dC and 5-methyl-dC to yield adducts (dG*, dC*, 5-methyl-dC*). The structures of dC* and 5-methyl-dC* were determined mainly by mass-, ¹H- and ¹³C-NMR- spectra. dC*: M+Na, m/e 344.1192 (344.1222 calcd. for C₁₅H₁₉N₃NaO₅); UV λ_{max} in H₂O, 227 nm. 5-methyl-dC*: M+Na, m/e 358.1372 (358.1379 calcd. for C₁₆H₂₁N₃NaO₅); UV λ_{max} in H₂O, 278 nm. The structure of dC* was confirmed by X-ray crystallography. After the reaction of 4-OHE with double stranded calf thymus DNA, the yield of these DNA modifications were dC* > 5-methyl-dC* > dG*. The more efficient formation of dC* than dG* in DNA may be due to

the fact that the amino group of dC in DNA is located in the major groove, while that of dG is in the minor groove and is more sterically hindered. As a prelude for testing its genotoxicity *in vivo*, 4-OHE (3 mg) was orally administered to mice, and after 24 h, the DNA was isolated from the esophagus, stomach, intestine, liver and kidney. The DNA was enzymatically digested to deoxynucleosides, and was subjected to LC/MS/MS analyses. Particularly, in the esophagus, stomach and intestine DNA, dC* was detected in the range of 2.0, 5.5 and 1.1 adducts / 10⁷ dC, respectively. Lower amounts of 5-methyl-dC* and dG* were also detected in these organ DNAs.

It is important to confirm the formation of 4-OHE in a model system of lipid peroxidation, as well as during the heat processing of edible vegetable oil, and during cooking. From ethylacetate traps (extracts) of the vapor phase released from the heated methyl linolenate-hemin model system, and the smoke released during the broiling of fish, 4-OHE was detected by GCMS. Commercial perilla oil, which is rich in linolenic acid (40–50 $\mu\text{g/g}$), the edible part of broiled fish (5–170 $\mu\text{g/g}$), and various fried foods (5–50 $\mu\text{g/g}$) also

contained high levels of 4-OHE. It was present at an especially high concentration (70–170 $\mu\text{g/g}$) in broiled saury. However, 4-oxo-2-nonenal⁵⁾, a cognate longer carbon chain derivative, was only detected in an one order of magnitude lower range in these food products. This may be due to the fact that the major natural ω -3 polyunsaturated fatty acids, such as linolenic acid, DHA and EPA, the precursor of 4-OHE, are more easily oxidized than ω -6 fatty acids, such as linoleic acid.

Workers involved in the manufacturing of vegetable oils, such as colza oil and soybean oil, which contain linolenic acid, will be exposed to 4-OHE during the crude oil extraction and purification. The same is true for workers manufacturing instant cup noodles and snack foods, and producing EPA and DHA from fish oil. Kitchen workers involved in frying foods or broiling fish in restaurants may also be exposed to 4-OHE. Since 4-OHE induces DNA adduct formation in experimental animal organs, it is possible that 4-OHE is an important human carcinogen. Further studies on the carcinogenicity of 4-OHE and its detection in working environments will be required.

Acknowledgement

We would like to thank Dr. T. Nohmi of the National Institute of Health Sciences, Tokyo, for providing us the *S. typhimurium* strains for the mutagenicity test.

References

- 1) Esterbauer H, Schaur, RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radical Biol Med* **11**, 81–128.
- 2) Horton AA, Fairhurst S (1987) Lipid peroxidation and mechanisms of toxicity. *Crit Rev Toxicol* **18**, 27–79.
- 3) Kasai H, Hayami H, Yamaizumi Z, Saito H, Nishimura S (1984) Detection and identification of mutagens and carcinogens as their adducts with guanosine derivatives. *Nucl Acids Res* **12**, 2127–36.
- 4) Narbury CJ, Zhivotovsky B (2004) DNA damage-induced apoptosis. *Oncogene* **23**, 2797–808.
- 5) Lee SH, Blair IA (2000) Characterization of 4-oxo-2-nonenal as a novel product of lipid peroxidation. *Chem Res Toxicol* **13**, 698–702.